- Conditions
- Food Addiction
- Interventions
- telomere length measure
- Diagnostic Test
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 70 Years
- Enrollment
- 120 participants
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Scottsbluff, Nebraska
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 112
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Positron Emission Tomography
- Interventions
- positron emission tomography scan
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 2
- States / cities
- San Diego, California • West Los Angeles, California
- Conditions
- Cardiovascular Disease, Diabetes, Dyslipidemia
- Interventions
- Man-made Trans FA, Natural Trans FA, Oleic Acid
- Dietary Supplement
- Lead sponsor
- UCSF Benioff Children's Hospital Oakland
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Oakland, California
- Conditions
- Telomeric 22Q13 Monosomy Syndrome, Tuberous Sclerosis, Hamartoma Syndrome, Multiple, Fragile X Syndrome, Angelman Syndrome, Rett Syndrome, Chromosome 15Q, Partial Deletion, Creatine Deficiency, X-linked
- Interventions
- Functional Behavioral Training (FBT), Positive Parenting Strategies-Treatment as Usual
- Behavioral · Other
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 2 Years to 12 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Atrial Fibrillation, Venous Thromboses, Heart Valve Diseases
- Interventions
- Fearon warfarin dosing algorithm, Usual care
- Other
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 22 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Facial Angiofibroma, Tuberous Sclerosis
- Interventions
- rapamycin, placebo
- Drug
- Lead sponsor
- Dermatology Specialties Limited Partnership
- Industry
- Eligibility
- 6 Years to 65 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • La Jolla, California • St. Petersburg, Florida + 3 more
- Conditions
- Fanconi Anemia
- Interventions
- Oxandrolone
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Not listed
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Fanconi Anemia
- Interventions
- Quercetin (dietary supplement)
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Friedreich Ataxia
- Interventions
- Omaveloxolone
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 2 Years to 15 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Healthy Subjects
- Interventions
- TR-701 FA with PSE, TR-701 FA Placebo with PSE
- Drug · Other
- Lead sponsor
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Alcohol Use Disorder
- Interventions
- Control, Functional Analysis, Cognitive Restructuring, Dealing With Cravings
- Behavioral
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Skin and Subcutaneous Tissue Bacterial Infections
- Interventions
- TR-701 FA, Linezolid
- Drug
- Lead sponsor
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 666 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 35
- States / cities
- Dothan, Alabama • Chula Vista, California • Escondido, California + 31 more
- Conditions
- Histiocytosis
- Interventions
- Trail Making Test, Parts A & B, Brief Test of Attention, Symbol Span, Controlled Oral Word Association Test, The Hopkins Verbal Learning Test-Revised, Brief Visuospatial Memory Test-Revised, Hospital Anxiety and Depression Scale, McGill Quality of Life Scale, MR Brain Imaging, Resting state functional MRI, Functional Assessment of Cancer Therapy Cognitive Scale (FACT-Cog)
- Behavioral · Diagnostic Test
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 4
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 1 more
- Conditions
- Asthma in Children
- Interventions
- Reach for Control, MATCH
- Behavioral
- Lead sponsor
- Wayne State University
- Other
- Eligibility
- 12 Years to 16 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Pancreatic Cancer
- Interventions
- CPI 613, Oxaliplatin, Irinotecan, 5-flurouracil, Folinic acid
- Drug
- Lead sponsor
- David Bajor, MD
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Autism Spectrum Disorder
- Interventions
- Standard FA+FCT, Pragmatic FA+FCT
- Behavioral
- Lead sponsor
- Matthew J O'Brien, PhD, BCBA-D
- Other
- Eligibility
- 18 Months to 83 Months
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Friedreich Ataxia 1
- Interventions
- Nicotinamide Riboside, Placebo, Exercise Intervention
- Dietary Supplement · Other
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 10 Years to 40 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Fanconi Anemia Complementation Group A
- Interventions
- RP-L102
- Biological
- Lead sponsor
- Rocket Pharmaceuticals Inc.
- Industry
- Eligibility
- 1 Year to 12 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Bacterial Infections
- Interventions
- TR-701 FA for injection, 200 mg/vial, TR-701 FA tablets
- Drug
- Lead sponsor
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Healthy Subjects
- Interventions
- TR-701 FA
- Drug
- Lead sponsor
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Recurrent Breast Carcinoma
- Interventions
- Abemaciclib, Biopsy Procedure, Biospecimen Collection, Copanlisib Hydrochloride, Diagnostic Imaging Testing, Echocardiography Test, Fulvestrant, Multigated Acquisition Scan
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Costa Mesa, California • Orange, California + 8 more
- Conditions
- Radiation Retinopathy
- Interventions
- Fluocinolone Acetonide (FA) implant
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Cobalamin, Dexamethasone, Docetaxel, Folic Acid, Gemcitabine, Nogapendekin Alfa, Pembrolizumab, Pemetrexed, Ramucirumab
- Dietary Supplement · Drug · Biological
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 350
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Little Rock, Arkansas + 280 more
- Conditions
- Allergy
- Interventions
- Neo-Synalar Cream, Sodium Lauryl Sulfate Aqueous Solution (0.40%), Saline
- Drug · Other
- Lead sponsor
- Noah Rosenberg, MD
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 206 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Fairfield, New Jersey